FTO and breast carcinoma: These breast cancer patients with distinct molecular subtypes all represented lower expression of FTO, METTL3, and METTL14, and higher expression of YTHDF1 and YTHDF3 in tumor compared to the corresponding adjacent samples (Supplementary Table S6 and Figure 2F).